

## Safety and Efficacy of RM-001, Autologous HBG1/2 Promoter-Modified CD34+Hematopoietic Stem and Progenitor Cells, in Transfusion-Dependent $\beta$ -Thalassemia

**Authors :** Rongrong Liu, Li Wang, Hui Xu, Jianpei Fang, Sixi Liu, Xiaolin Yin, Junbin Liang, Gaohui Yan, Yaoyun Li, Yali Zhou, Xinyu Li, Yue Li, Lei Shi, Yongrong Lai, Junjiu Huang, Xinhua Zhang

**Abstract :** Background: Beta-Thalassemia is caused by reduced ( $\beta^+$ ) or absent ( $\beta^0$ ) synthesis of the  $\beta$ -globin chains of hemoglobin. Transfusions and oral iron chelation therapy have improved the quality of life for patients with Transfusion-Dependent thalassemia (TDT). Recent advances in genome editing platforms of CRISPR-Cas9 have paved the way for induction of HbF by reactivating expression of  $\gamma$ -chain. Aims: We performed CRISPR-Cas9-mediated genome editing of hematopoietic stem cells to mutate HBG1/HBG2 promoter sequence, thereby representing a naturally occurring HPFH-like mutation, producing RM-001. Here, we present an initial assessment of safety and efficacy of RM-001 in patients with TDT. Methods: Patients (6-35 y of age) with TDT receiving packed red blood cell (pRBC) transfusions of  $\geq 100$  mL/kg/y or  $\geq 10$  units/y in the previous 2 y were eligible. CD34+ cells were edited with CRISPR-Cas9 using a guide RNA specific for the binding site of BCL11A on the HBG1/2 promoter. Prior to RM-001 product infusion (day 0), patients received myeloablative conditioning with Busulfan from day-7 to day-4. Patients were monitored for AEs Hb expression. Results: Data cut as of 28 Feb 2024, 16 TDT patients have been treated with RM-001 and followed  $\geq 3$  months. 5 of these 16 patients had finished their 24 months follow up. Eleven patients have  $\beta^0/\beta^0$  genotype and five patients have  $\beta^0/\beta^+$  genotype. In addition to  $\beta$ -thalassemia, two patients had  $\alpha$ -deletion with the genotype of  $--/\alpha\alpha$ . Efficacy: All patients received a single dose intravenous infusion of RM-001 cells. 5 of them had been followed 24 months or longer. All patients achieved transfusion-independent (TI, total Hb continued  $\geq 9$ g/dL) (Figure1). Patients demonstrated sustained and clinically meaningful increases in HbF levels since 4 month post-RM-001 infusion (Figure.2). Total hemoglobin in all patients was stable at 10-12g/dL during the follow-up period. Safety: The adverse events observed after RM-001 infusion were consistent with those that are typical of Busulfan-based myeloablation. The allelic editing analysis at 6-month visit showed that the on-target allelic editing frequency in bone marrow cells was 73.44% (64.65% to 84.6%, n=13). Summary/Conclusion: This interim analysis, in which all the 19 patients age from 7.9 to 25yo met the success criteria for the trial with respect to transfusion independence, showed that autologous HBG1/2 promoter-modified CD34+ HSPCs gene therapy resulted in an adequate amount of HbF as early as 2 months after infusion led to near-normal hemoglobin levels, remained transfusion-free through the reported period without product related SAE. After RM-001 infusion, high levels of HbF proportion and on-target editing in bone marrow cells were maintained. Submitted on behalf of the RM-001 Investigators.

**Keywords :** thalassemian, genetherapy, CRISPR/Cas9, HbF

**Conference Title :** ICH 2024 : International Conference on Hematology

**Conference Location :** Dubai, United Arab Emirates

**Conference Dates :** December 23-24, 2024